Novo Nordisk says weekly IcoSema superior to daily insulin glargine, aspart

COPENHAGEN (Reuters) – Denmark’s Novo Nordisk said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling blood sugar level in people with type 2 diabetes compared to daily injections of insulin glargine combined with the insulin aspart.

(Reporting by Louise Breusch Rasmussen, editing by Terje Solsvik)